Establishment Labs Holdings Inc. Common Shares (ESTA) Stock
Key stats
- Market cap
- $1.89B
- Price / Earnings ratio
- -47.7x
- EPS (TTM)
- -$1.69
- Volume
- Loading
- 52-week high
- $97.59
- 52-week low
- $47.00
Source: third-party data provider, as of October 24, 2026
Compare with ESTA
Recent news

Establishment Labs Holdings Inc. (ESTA) Expected to Beat Earnings Estimates: Should You Buy?
Establishment Labs Holdings Inc. (ESTA) Expected to Beat Earnings Estimates: Should You Buy?
ESTA

Establishment Labs® to Announce Third Quarter 2026 Financial Results on October 29
Establishment Labs® to Announce Third Quarter 2026 Financial Results on October 29
ESTA

Establishment Labs® Receives FDA Approval for Additional Sizes of Motiva Implants®
Establishment Labs® Receives FDA Approval for Additional Sizes of Motiva Implants®
ESTA

Establishment Labs® Highlights New Breast Tissue Preservation Data and Announces Minimally Invasive Product Extensions at the 11th World Symposium on Ergonomic Implants
Establishment Labs® Highlights New Breast Tissue Preservation Data and Announces Minimally Invasive Product Extensions at the 11th World Symposium on Ergonomic Implants
ESTA
News tone: automated (AI) classification of the article's content, not a price prediction.
Technical indicators
- RSI 14
- 48.39
- MACD 12/26/9
- -2.33
- EMA 9 of MACD
- -2.88
- MACD histogram
- 0.55
- SMA 50
- $68.21
- Price below SMA 50
- EMA 50
- $67.97
- Price below EMA 50
- SMA 200
- $72.45
- Price below SMA 200
- EMA 200
- $70.17
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of October 22, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Buy
Based on 5 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
No data available
Source: third-party data provider
Latest news

Establishment Labs Holdings Inc. (ESTA) Expected to Beat Earnings Estimates: Should You Buy?
Establishment Labs Holdings Inc. (ESTA) Expected to Beat Earnings Estimates: Should You Buy?
ESTA

Establishment Labs® to Announce Third Quarter 2026 Financial Results on October 29
Establishment Labs® to Announce Third Quarter 2026 Financial Results on October 29
ESTA

Establishment Labs® Receives FDA Approval for Additional Sizes of Motiva Implants®
Establishment Labs® Receives FDA Approval for Additional Sizes of Motiva Implants®
ESTA

Establishment Labs® Highlights New Breast Tissue Preservation Data and Announces Minimally Invasive Product Extensions at the 11th World Symposium on Ergonomic Implants
Establishment Labs® Highlights New Breast Tissue Preservation Data and Announces Minimally Invasive Product Extensions at the 11th World Symposium on Ergonomic Implants
ESTA

Establishment Labs Q2 Earnings Call Highlights
Establishment Labs Q2 Earnings Call Highlights
ESTA

Establishment Labs Holdings Inc. (ESTA) Reports Q2 Loss, Tops Revenue Estimates
Establishment Labs Holdings Inc. (ESTA) Reports Q2 Loss, Tops Revenue Estimates
ESTA

Establishment Labs® Reports Second Quarter 2026 Financial Results
Establishment Labs® Reports Second Quarter 2026 Financial Results
ESTA

Establishment Labs® to Announce Second Quarter 2026 Financial Results on August 6
Establishment Labs® to Announce Second Quarter 2026 Financial Results on August 6
ESTA

A Hedge Fund Dumped Establishment Labs Shares Worth $6.6 Million. Here's a Closer Look at the Transaction.
A Hedge Fund Dumped Establishment Labs Shares Worth $6.6 Million. Here's a Closer Look at the Transaction.
ESTA

Establishment Labs® Appoints Taylor Harris to Board of Directors
Establishment Labs® Appoints Taylor Harris to Board of Directors
ESTA
News tone: automated (AI) classification of the article's content, not a price prediction.
About Establishment Labs Holdings Inc. Common Shares
Establishment Labs Holdings Inc is a medical technology company engaged in offering medical devices and aesthetic products. It is involved in the designing, manufacturing, and marketing of silicone-filled breast and body-shaping implants. The company markets its products under Motiva implants Brand. It distributes its products to medical distributors; and physicians, hospitals, and clinics in the form of direct sales. Its geographical segments are Europe, Latin America, Asia-Pacific/Middle East, and Others.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Mr. Fillipo Peter Caldini | CEO & Director | 1965 |
| Ms. Cassandra E. Harris | Senior VP & CFO | 1973 |
| Mr. S. Ross Mansbach | General Counsel, Chief Compliance Officer & Chief Human Resources Officer | 1967 |
| Mr. Roberto de Mezerville | Chief Technology Officer | 1980 |
| Ms. Malavika William | VP, Global Head of Marketing & Communications | — |
| Mr. Ivan Bilic | Senior Vice President of Commercial Operations - OUS | — |
| Mr. Jeff Ehrhardt | Senior VP & GM of North America | — |
Fundamentals
Valuation
Profitability
Trading
Source: third-party data provider, as of October 24, 2026
Technical indicators
- RSI 14
- 48.39
- MACD 12/26/9
- -2.33
- EMA 9 of MACD
- -2.88
- MACD histogram
- 0.55
- SMA 50
- $68.21
- Price below SMA 50
- EMA 50
- $67.97
- Price below EMA 50
- SMA 200
- $72.45
- Price below SMA 200
- EMA 200
- $70.17
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of October 22, 2026. Technical data, not a recommendation.
Analyst views
5 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
- Low
- $92.00
- Average
- $100.40
- High
- $117.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -1.5 | +10.5 | -25.4 | +16.9 | +0.7 | +26.0 | +3.7 | -25.3 | -7.7 | -1.2 |



